오늘본 상품

Product Name :
CymaxTM Human IL-10 ELISA Kit
Product Type :
Kits
Application(추가정보) :
sELISA
Reactivity :
Human
Storage :
All kit components of this kit are stable at 2 to 8°C. Any unused reconstituted standard should be discarded or frozen at -70°C. Standard can be frozen and thawed one time only without loss of immunoreactivity.
Sensitivity :
< 0.820 pg/ml
Sample Type :
Human serum, plasma, body fluids, tissue lysates, cell culture supernates, buffered solution
Form :
Pre-coated plate
Detection range :
7.8~500 pg/ml
Background :
Interleukin-10, also called cytokine synthesis inhibitory factor, is implicated in tumorigenesis, and it has been shown that polymorphisms in its gene promoter correlate with differential amounts of production. IL-10 is an important cytokine with anti-inflammatory, anti-immune, and antifibrotic functions. It is also an important regulatory cytokine whose involvement extends into diverse areas of the human immune system. IL-10 is a recently described natural endogenous immunosuppressive cytokine that has been identified in human, murine, and other organisms. IL-10 significantly affects chemokine biology, because human IL-10 inhibits chemokine production and is a specific chemotactic factor for CD8+ T cells. It suppresses the ability of CD4+ T cells, but not CD8+ T cells, to migrate in response to IL-8. Interleukin-10 gene polymorphisms and interleukin-10 production capability may contribute to the development of skin squamous cell carcinomas after renal transplantation. The interleukin-10 locus contributes to the heritability of psoriasis susceptibility. With regard to sudden infant death, IL-10 is of special interest. This is an immunoregulatory cytokine that plays an important role in the development of infectious disease. The mIL-10 gene is mapped to mouse chromosome 1 and the hIL-10 gene is also mapped to human chromosome. The standard product used in this kit is recombinant human IL-10, consisting of 160 amino acids with the molecular mass of 18.6KDa.
Background reference :
1) Alamartine, E.; Berthoux, P.; Mariat, C.; Cambazard, F.; Berthoux, F. Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. J. Invest. Derm. 120: 99-103, 2003.
2) Grove, J.; Daly, A. K.; Bassendine, M. F.; Gilvarry, E.; Day, C. P. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 46: 540-545,2000.
3) Eskdale, J.; Kube, D.; Tesch, H.; Gallagher, G. Mapping of the human IL10 gene and further characterization of the 5-prime flanking sequence. Immunogenetics 46: 120-128, 1997.
4) Gesser, B.; Leffers, H.; Jinquan, T.; Vestergaard, C.; Kirstein, N.; Sindet-Pedersen, S.; Jensen, S. L.; Thestrup-Pedersen, K.; Larsen, C. G. Identification of functional domains on human interleukin 10. Proc. Nat. Acad. Sci. 94: 14620-14625, 1997.
5) Asadullah, K.; Eskdale, J.; Wiese, A.; Gallagher, G.; Friedrich, M.; Sterry, W. Interleukin-10 promoter polymorphism in psoriasis. J. Invest. Derm. 116: 975-978, 2001.
6) Opdal, S. H.; Opstad, A.; Vege, A.; Rognum, T. O. IL-10 gene polymorphisms are associated with infectious cause of sudden infant death. Hum. Immun. 64: 1183-1189, 2003.
7) Kim, J. M.; Brannan, C. I.; Copeland, N. G.; Jenkins, N. A.; Khan, T. A.; Moore, K. W.Structure of the mouse Il-10 gene and chromosomal localization of the mouse and human genes.
Database link - SwissProt no.
P22301